Serum transaminases in children with Wilson's disease

被引:46
作者
Iorio, R
D'Ambrosi, M
Marcellini, T
Barbera, C
Maggiore, G
Zancan, L
Giacchino, L
Vajro, P
Marazzi, MG
Francavilla, T
Michielutti, F
Resti, M
Frediani, J
Pastore, M
Mazzarella, G
Fusco, G
Cirillo, F
Vegnente, A
机构
[1] Univ Naples Federico II, Dept Paediat, I-80131 Naples, Italy
[2] IRCCS Bambin Gesu, Rome, Italy
[3] Univ Turin, I-10124 Turin, Italy
[4] Univ Pisa, I-56100 Pisa, Italy
[5] Univ Padua, I-35100 Padua, Italy
[6] IRCCS G Gaslini, Genoa, Italy
[7] Univ Genoa, I-16126 Genoa, Italy
[8] Univ Bari, I-70121 Bari, Italy
[9] Osped Sacro Cuore Negrar, Verona, Italy
[10] Univ Florence, I-50121 Florence, Italy
[11] Univ Roma La Sapienza, Rome, Italy
关键词
penicillamine; zinc; copper; liver disease; patients compliance;
D O I
10.1097/00005176-200410000-00006
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Objectives: The response of serum transaminase levels to penicillamine and zinc treatment in Wilson's disease is poorly understood. The aim of this multicenter retrospective study was to evaluate transaminase levels after penicillamine and zinc treatment in children with Wilson's disease. Patients and Methods: One hundred and nine patients with Wilson's disease (median age at diagnosis, 7.2 years; range, 1 to 18 years), treated for at least 12 months and observed in the last 20 years at 11 Paediatric Departments were studied. Clinical, laboratory and histologic features at diagnosis and initial treatment were recorded. Efficacy parameters were normalization of serum transaminase level and improved clinical and/or laboratory signs. One hundred and two patients had clinical or laboratory signs of liver disease. Results: Fifty-six of 87 patients (64%) given penicillamine normalized serum alanine aminotransferase (ALT) levels within a median of 17 months (range, 2 to 96 months). Of the 29 patients with persistent hyper-ALT, 17 (59%) switched to zinc; only four of these normalized ALT on zinc within a (50%) of the 22 patients given zinc alone normalized ALT within a median period of 6 months (range, 1 to 36 months). Of the 11 patients with persistent hyper-ALT, five switched to penicillamine. Three of the five normalized ALT within a median period of 6 months (range, 6 to 9 months). Overall, in penicillamine-treated and zinc-treated patients with persistent hypertransaminasemia, ALT decreased from a basal median of 236 IU/L (range, 54 to 640 IU/L) to a median of 78 (range, 46 to 960 IU/L) at the end of follow-up (P = 0.0245). Poor compliance was suspected in only 10% of cases. No predictive factor of persistent hypertransaminasemia was identified. Liver disease did not worsen in any patient during the study. Conclusions: Although the efficacy of penicillamine and zinc is well documented, it is notable that a subset of children with Wilson's disease-related liver disease (36%) had hypertransaminasemia despite appropriate treatment with penicillamine or zinc. (C) 2004 Lippincott Williams Wilkins.
引用
收藏
页码:331 / 336
页数:6
相关论文
共 35 条
[1]   TREATMENT OF WILSONS-DISEASE WITH AMMONIUM TETRATHIOMOLYBDATE .1. INITIAL THERAPY IN 17 NEUROLOGICALLY AFFECTED PATIENTS [J].
BREWER, G ;
DICK, RD ;
JOHNSON, V ;
WANG, YX ;
YUZBASIYANGURKAN, V ;
KLUIN, K ;
FINK, JK ;
AISEN, A .
ARCHIVES OF NEUROLOGY, 1994, 51 (06) :545-554
[2]   INITIAL THERAPY OF PATIENTS WITH WILSONS-DISEASE WITH TETRATHIOMOLYBDATE [J].
BREWER, GJ ;
DICK, RD ;
YUZBASIYANGURKIN, V ;
TANKANOW, R ;
YOUNG, AB ;
KLUIN, KJ .
ARCHIVES OF NEUROLOGY, 1991, 48 (01) :42-47
[3]   WILSON DISEASE [J].
BREWER, GJ ;
YUZBASIYANGURKAN, V .
MEDICINE, 1992, 71 (03) :139-164
[4]  
BREWER GJ, 1994, J LAB CLIN MED, V123, P849
[5]   ORAL ZINC THERAPY FOR WILSONS-DISEASE [J].
BREWER, GJ ;
HILL, GM ;
PRASAD, AS ;
COSSACK, ZT ;
RABBANI, P .
ANNALS OF INTERNAL MEDICINE, 1983, 99 (03) :314-320
[6]   Treatment of Wilson's disease with zinc: XV - Long-term follow-up studies [J].
Brewer, GJ ;
Dick, RD ;
Johnson, VD ;
Brunberg, JA ;
Kluin, KJ ;
Fink, JK .
JOURNAL OF LABORATORY AND CLINICAL MEDICINE, 1998, 132 (04) :264-278
[7]  
BREWER GJ, 1993, J AM COLL NUTR, V12, P26
[8]   Treatment of Wilson's disease with zinc XVI: Treatment during the pediatric years [J].
Brewer, GJ ;
Dick, RD ;
Johnson, VD ;
Fink, JK ;
Kluin, KJ ;
Daniels, S .
JOURNAL OF LABORATORY AND CLINICAL MEDICINE, 2001, 137 (03) :191-198
[9]   VALUE OF URINARY COPPER EXCRETION AFTER PENICILLAMINE CHALLENGE IN THE DIAGNOSIS OF WILSONS-DISEASE [J].
DACOSTA, CM ;
BALDWIN, D ;
PORTMANN, B ;
LOLIN, Y ;
MOWAT, AP ;
MIELIVERGANI, G .
HEPATOLOGY, 1992, 15 (04) :609-615
[10]  
Friedman L S, 1993, Gastroenterology, V104, P1566